155 related articles for article (PubMed ID: 32025571)
1. Malaria elimination transmission and costing in the Asia-Pacific: Developing an investment case.
Shretta R; Silal SP; Celhay OJ; Gran Mercado CE; Kyaw SS; Avancena A; Fox K; Zelman B; Baral R; White LJ; Maude RJ
Wellcome Open Res; 2019; 4():60. PubMed ID: 32025571
[No Abstract] [Full Text] [Related]
2. Estimating the risk of declining funding for malaria in Ghana: the case for continued investment in the malaria response.
Shretta R; Silal SP; Malm K; Mohammed W; Narh J; Piccinini D; Bertram K; Rockwood J; Lynch M
Malar J; 2020 Jun; 19(1):196. PubMed ID: 32487148
[TBL] [Abstract][Full Text] [Related]
3. Investment case for malaria elimination in South Africa: a financing model for resource mobilization to accelerate regional malaria elimination.
Njau J; Silal SP; Kollipara A; Fox K; Balawanth R; Yuen A; White LJ; Moya M; Pillay Y; Moonasar D
Malar J; 2021 Aug; 20(1):344. PubMed ID: 34399767
[TBL] [Abstract][Full Text] [Related]
4. An economic analysis of malaria elimination program in Nepal.
Paudel U; Pant KP
Heliyon; 2020 May; 6(5):e03886. PubMed ID: 32395658
[TBL] [Abstract][Full Text] [Related]
5. Using donor funding to catalyse investment in malaria prevention in Ghana: an analysis of the potential impact on public and private sector expenditure.
Paintain L; Kpabitey R; Nyanor-Fosu F; Piccinini Black D; Bertram K; Webster J; Goodman C; Lynch M
Malar J; 2022 Jun; 21(1):203. PubMed ID: 35761255
[TBL] [Abstract][Full Text] [Related]
6. How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis.
Kastner RJ; Sicuri E; Stone CM; Matwale G; Onapa A; Tediosi F
PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005934. PubMed ID: 28949987
[TBL] [Abstract][Full Text] [Related]
7. The US President's Malaria Initiative, Plasmodium falciparum transmission and mortality: A modelling study.
Winskill P; Slater HC; Griffin JT; Ghani AC; Walker PGT
PLoS Med; 2017 Nov; 14(11):e1002448. PubMed ID: 29161259
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Investment case for primary health care in low- and middle-income countries: A case study of Kenya.
Mwai D; Hussein S; Olago A; Kimani M; Njuguna D; Njiraini R; Wangia E; Olwanda E; Mwaura L; Rotich W
PLoS One; 2023; 18(3):e0283156. PubMed ID: 36952482
[TBL] [Abstract][Full Text] [Related]
10. An Investment Case to Prevent the Reintroduction of Malaria in Sri Lanka.
Shretta R; Baral R; Avanceña ALV; Fox K; Dannoruwa AP; Jayanetti R; Jeyakumaran A; Hasantha R; Peris L; Premaratne R
Am J Trop Med Hyg; 2017 Mar; 96(3):602-615. PubMed ID: 28115673
[TBL] [Abstract][Full Text] [Related]
11. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
[TBL] [Abstract][Full Text] [Related]
12. Predicting the cost of malaria elimination in the Asia-Pacific.
Shretta R; Silal S; White LJ; Maude RJ
Wellcome Open Res; 2019; 4():73. PubMed ID: 31080895
[TBL] [Abstract][Full Text] [Related]
13. Global investment targets for malaria control and elimination between 2016 and 2030.
Patouillard E; Griffin J; Bhatt S; Ghani A; Cibulskis R
BMJ Glob Health; 2017; 2(2):e000176. PubMed ID: 29242750
[TBL] [Abstract][Full Text] [Related]
14. Investment case for small and sick newborn care in Tanzania: systematic analyses.
Kamuyu R; Tarus A; Bundala F; Msemo G; Shamba D; Paul C; Tillya R; Murless-Collins S; Oden M; Richards-Kortum R; Powell-Jackson T; Kumar MB; Salim N; Lawn JE
BMC Pediatr; 2023 Dec; 23(Suppl 2):632. PubMed ID: 38098013
[TBL] [Abstract][Full Text] [Related]
15. Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study.
Griffin JT; Bhatt S; Sinka ME; Gething PW; Lynch M; Patouillard E; Shutes E; Newman RD; Alonso P; Cibulskis RE; Ghani AC
Lancet Infect Dis; 2016 Apr; 16(4):465-72. PubMed ID: 26809816
[TBL] [Abstract][Full Text] [Related]
16. A global investment case for hepatitis B elimination: a modelling study.
Seaman CP; Luong P; Xiao Y; Abeysuriya R; Howell J; Hellard M; Scott N
Lancet Gastroenterol Hepatol; 2023 Oct; 8(10):932-942. PubMed ID: 37517417
[TBL] [Abstract][Full Text] [Related]
17. The Investment Case for Malaria Elimination in Thailand: A Cost-Benefit Analysis.
Sudathip P; Kongkasuriyachai D; Stelmach R; Bisanzio D; Sine J; Sawang S; Kitchakarn S; Sintasath D; Reithinger R
Am J Trop Med Hyg; 2019 Jun; 100(6):1445-1453. PubMed ID: 30994098
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of malaria elimination in Sampov Loun Operational District, Cambodia.
Por I; Sovannaroth S; Moran A; Dysoley L; Nguon S; Bunthy O; Meas MS; Barat L; Slot R; Thangadurai S; Kapella BK; Hassan SE; Po L; An SS; Gimnig JE; McDowell M; Thigpen M; Armistead J; AlMossawi HJ; Kheang ST; Kak N
Malariaworld J; 2020; 11():2. PubMed ID: 34532221
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
